Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and Innovative" small giant enterprise [1] - The latest financial results show a revenue of 86.11 million yuan for the third quarter of 2024, representing a year-on-year decrease of 13.44%, with a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] Group 2 - The company's current price-to-earnings (P/E) ratio is -25.68, with a price-to-book (P/B) ratio of 5.45 and a total market capitalization of 1.489 billion yuan [2] - The industry average P/E ratio is 48.08, while the industry median is 30.21, indicating that the company is significantly below industry benchmarks [2] - The company has experienced a net outflow of 15.09 million yuan in principal funds on April 22, with a total outflow of 40.22 million yuan over the past five days [1]
辰光医疗收盘下跌5.40%，最新市净率5.45，总市值14.89亿元